Clinical trials: Leukemia, Acute Myelogenous (AML)
Acute Myeloid Leukemia
The CLARA Study From the Acute Leukemia French Association (ALFA 0702 Trial)
This study is a phase II randomized multicenter study. Patients will be enrolled at time of diagnosis and will receive one or two cycles of induction chemotherapy.
- Trial name
- CLARA (NCT00932412)
- Testing
- CLARA, HDAc
- Where
- 34 sites in France
- Volunteers
- 735 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia
Phase I Study of Q702 With Azacitidine and Venetoclax for Relapsed or Refractory Acute Myeloid Leukemia
To learn about the safety and tolerability of the drug combination of Q702, azacitidine, and venetoclax when given to participants with relapsed/refractory AML.
- Trial name
- NCT06445907
- Testing
- Azacitidine, Venetoclax, Q702
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Multiple Myeloma, Acute Myeloid Leukemia
Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT
The purpose of this study is to see whether hematopoietic stem cell transplant (HSCT) patients can consistently eat a diet rich in prebiotics.
- Conditions
- Multiple Myeloma, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma
- Trial name
- HCTDiet (NCT04629430)
- Testing
- Pre-biotic foods/drinks
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Virginia
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.
- Trial name
- NCT01433965
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Davis
Acute Myeloid Leukemia, Stem Cell Leukemia
Nalbuphine Versus Morphine for Mucositis Pain in Pediatric Cancer Patients
Evaluation of safety and efficacy of Nalbuphine versus Morphine patient controlled analgesia (PCA) for mucositis pain in pediatric cancer patients
- Trial name
- PCA (NCT03825887)
- Testing
- Nalbuphine, Morphine
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
This pilot clinical trial aims to assess feasibility and tolerability of using an LINAC based "organ-sparing marrow-targeted irradiation" to condition patients with high-risk hematological malignancies who are otherwise…
- Conditions
- Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)
- Trial name
- NCT02122081
- Testing
- radiation therapy, cyclophosphamide, anti-thymocyte globulin
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Sumithira Vasu
Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia
Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
Relapsed or refractory acute leukemia (R/R AL) is a life-threatening blood cancer with poor outcomes and limited treatment options.
- Conditions
- Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Lymphoblastic Leukemia, Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Trial name
- R/R AL (NCT07696481)
- Testing
- PID23 Injection
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Zhujiang Hospital
Leukemia
A Randomized Phase III Study of Intensive Consolidation With High Dose Cytosine Arabinoside in Acute Myelogenous Leukemia (AML-8B)
RATIONALE: Patient abstract not available PURPOSE: Patient abstract not available
- Trial name
- NCT01324063
- Testing
- sargramostim, amsacrine, cytarabine
- Volunteers
- 160 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
This phase I trial studies the side effects and best dose of oxidative phosphorylation inhibitor IACS-010759 in treating patients with acute myeloid leukemia that has come back or does not respond to treatment.
- Trial name
- NCT02882321
- Testing
- Oxidative Phosphorylation Inhibitor IACS-010759, Pharmacological Study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
AML
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
This is a non-randomized, open-label, single-arm, dose-escalation Phase I study to evaluate the safety and tolerability of MAX-40279-01 in patients with Relapsed or Refractory AML.
- Trial name
- NCT04187495
- Testing
- MAX-40279-01
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Maxinovel Pty., Ltd.
Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
This phase I trial studies the side effects of DEC-205/NY-ESO-1 fusion protein CDX-1401, poly ICLC, decitabine, and nivolumab in treating patients with myelodysplastic syndrome or acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome
- Trial name
- NCT03358719
- Testing
- DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Roswell Park Cancer Institute
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS)
Panobinostat Maintenance After HSCT fo High-risk AML and MDS
Aim of this prospective randomized trial is to compare maintenance treatment with panobinostat interspersed with donor lymphocyte infusions (DLI) versus the standard approach of pre-emptive DLI alone in patients with poor-risk…
- Trial name
- NCT04326764
- Testing
- Panobinostat
- Where
- 19 sites in Germany, Netherlands
- Volunteers
- 52 people
- Sponsor
- Goethe University
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome.
Master Protocol: The main goal of this master clinical trial study is to assesses the safety, tolerability, pharmacokinetic (PK), Pharmacodynamic (PD) in participants with relapsed or refractory acute myeloid leukemia (AML) or…
- Trial name
- NCT05457010
- Testing
- SPRX002, ARC-T Cells, Cyclophosphamide
- Where
- 5 sites in United States
- Volunteers
- 24 people
- Sponsor
- Kite, A Gilead Company
Acute Myeloid Leukemia
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
This study is an open-label, single arm phase II study which will examine the efficacy and toxicity of the combination therapy of GO, mitoxantrone and etoposide in patients who did not respond to first line induction therapy.
- Trial name
- NCT03839446
- Testing
- mitoxantrone + etoposide + gemtuzumab ozogamicin
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Robert Redner, MD
Neoplasms, Hematologic Neoplasms
Research Development（RD）13-02 Chimeric Antigen Receptor(CAR) -T Cell Injection for Patients With r/r Cluster Of Differentiation 7（CD7）+ T-Acute Lymphoblastic Leukemia(ALL)/T-Lymphoblastic Lymphoma(LBL) /Acute Myelogenous Leukemia(AML)
This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 CAR-T therapy for patients with CD7-positive relapsed or refractory T-ALL/LBL/AML, and to evaluate the…
- Conditions
- Neoplasms, Hematologic Neoplasms, Hematologic Diseases
- Trial name
- NCT05907603
- Testing
- RD13-02 cell infusion
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Kai Lin Xu，MD
Acute Myeloid Leukemia, Adult
Individualized Induction Therapy for Non-elderly Acute Myeloid Leukemia Patients With Adverse Risk Features
Individualized induction therapy will be applied to the non-elderly acute myeloid leukemia (AML) patients with adverse genetic risk features guided by rapid screening with fluorescence in situ hybridization (FISH) and…
- Trial name
- NCT04752527
- Testing
- venetoclax combined with decitabine
- Where
- China
- Volunteers
- 42 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Leukemia, Myelodysplastic Syndromes
Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia
RATIONALE: Monoclonal antibodies can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00618696
- Testing
- anti-CD45 monoclonal antibody AHN-12, yttrium Y 90 anti-CD45 monoclonal antibody AHN-12
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Nonlymphocytic, Acute
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
The purpose of this study is to evaluate the effectiveness (response rate) and safety of tipifarnib in patients with refractory or relapsed AML.
- Trial name
- NCT00354146
- Testing
- tipifarnib (R115777)
- Volunteers
- 252 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Leukemia
Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy
RATIONALE: Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00739388
- Testing
- azacytidine
- Where
- 11 sites in Switzerland
- Volunteers
- 47 people
- Sponsor
- Swiss Cancer Institute
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.